{"abstract":"The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled \"Role of HIV Resistance Testing in Antiretroviral Drug Development.\" This guidance is intended to assist sponsors in the clinical development of drugs for the treatment of human immunodeficiency virus (HIV) infection. Specifically, this guidance addresses the agency's current thinking regarding the role of HIV resistance testing during antiretroviral drug development and postmarketing. This guidance discusses important nonclinical studies that are recommended before the initiation of phase 1 clinical studies in HIV-infected patients. In addition, this guidance addresses the use of resistance testing in clinical phases of drug development and recommends the type of information that should be collected and the types of analyses that should be conducted to characterize an antiretroviral's resistance profile. This guidance finalizes the draft guidance published on November 29, 2004.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2007/10/31/E7-21403.html","cfr_references":[],"citation":"72 FR 61656","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Submit written or electronic comments on agency guidances at any time.","disposition_notes":null,"docket_ids":["Docket No. 2004D-0484"],"dockets":[],"document_number":"E7-21403","effective_on":null,"end_page":61657,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2007/10/31/E7-21403.xml","html_url":"https://www.federalregister.gov/documents/2007/10/31/E7-21403/guidance-for-industry-on-the-role-of-human-immunodeficiency-virus-resistance-testing-in","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/E7-21403?publication_date=2007-10-31","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2007-10-31/E7-21403/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":47,"last_updated":"2026-11-22 14:15:04 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-10-31/pdf/E7-21403.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":null,"publication_date":"2007-10-31","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2007/10/31/E7-21403.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2011-11-13T08:05:31Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":61656,"subtype":null,"title":"Guidance for Industry on the Role of Human Immunodeficiency Virus Resistance Testing in Antiretroviral Drug Development; Availability","toc_doc":"Antiretroviral drug development; role of HIV resistance testing","toc_subject":"Reports and guidance documents; availability, etc.:","topics":[],"type":"Notice","volume":72}